'''Levomethadone''' ([[International Nonproprietary Name|INN]]; '''<small>L</small>-Polamidon''', '''<small>L</small>-Polamivet''', '''Levadone''', '''Levothyl'''), or '''levamethadone''', is a [[Chemical synthesis|synthetic]] [[opioid]] [[analgesic]] and [[antitussive]] which is marketed in [[Europe]] and is used for [[pain management]] and in [[opioid replacement therapy|opioid maintenance therapy]].<ref name="Buschmann2002" /><ref name="Macdonald1997">{{cite book | author = F.. Macdonald | title = Dictionary of Pharmacological Agents | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA1294 | accessdate = 17 May 2012 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 1294}}</ref><ref name="Index Nominum 2000: International Drug Directory">{{cite book | title = Index Nominum 2000: International Drug Directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA605 | accessdate = 17 May 2012 | year = 2000 | publisher = Taylor & Francis US | isbn = 978-3-88763-075-1 | page = 605}}</ref> In addition to being used as a [[pharmaceutical]] [[drug]] itself, levomethadone, or ''R''-(−)-methadone, is the [[biological activity|active]] [[enantiomer]] of [[methadone]],<ref name="Macdonald1997" /> having approximately 50x the [[potency (pharmacology)|potency]] of the ''S''-(+)-enantiomer as well as greater [[μ-opioid receptor]] [[binding selectivity|selectivity]].<ref name="Buschmann2002" /><ref name="FörchSchönherr2009">{{cite book | author1 = Renate Förch | author2 = Holger Schönherr | author3 = A. Tobias A. Jenkins | title = Surface Design: Applications in Bioscience and Nanotechnology | url = https://books.google.com/books?id=J0fhTBYVJioC&pg=PA193 | accessdate = 17 May 2012 | date = 11 August 2009 | publisher = Wiley-VCH | isbn = 978-3-527-40789-7 | page = 193}}</ref> Accordingly, it is about twice as potent as methadone by weight and its effects are virtually identical in comparison.<ref name="BrueraYennurajalingam2011">{{cite book | author1 = Eduardo Bruera | author2 = Sriram Yennurajalingam | title = Oxford American Handbook of Hospice and Palliative Medicine | url = https://books.google.com/books?id=I1laHM-HP1QC&pg=PA43 | accessdate = 17 May 2012 | date = 16 August 2011 | publisher = Oxford University Press | isbn = 978-0-19-538015-6 | page = 43}}</ref><ref name="pmid15916866">{{cite journal  |vauthors=Verthein U, Ullmann R, Lachmann A, etal | title = The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study | journal = Drug and Alcohol Dependence | volume = 80 | issue = 2 | pages = 267–71 |date=November 2005 | pmid = 15916866 | doi = 10.1016/j.drugalcdep.2005.04.007 | url = http://linkinghub.elsevier.com/retrieve/pii/S0376-8716(05)00150-X}}</ref> In addition to its activity at the [[opioid receptor]]s, levomethadone has been found to act as a weak [[competitive inhibition|competitive]] [[receptor antagonist|antagonist]] of the [[NMDA receptor|''N''-methyl-<small>D</small>-aspartate (NMDA) receptor complex]]<ref name="StrainStitzer2005">{{cite book | author1 = Eric C. Strain | author2 = Maxine L. Stitzer | title = The Treatment of Opioid Dependence | url = https://books.google.com/books?id=entNMgTdeJ4C&pg=PA63 | accessdate = 19 May 2012 | date = 4 November 2005 | publisher = JHU Press | isbn = 978-0-8018-8303-3 | page = 63}}</ref> and as a potent [[noncompetitive inhibition|noncompetitive]] antagonist of the [[α3β4-nicotinic receptor|α<sub>3</sub>β<sub>4</sub> nicotinic acetylcholine (nACh) receptor]].<ref name="pmid11561100">{{cite journal |vauthors=Xiao Y, Smith RD, Caruso FS, Kellar KJ | title = Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 299 | issue = 1 | pages = 366–71 |date=October 2001 | pmid = 11561100 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11561100}}</ref>
